Absolutely no mention of AstraZeneca, at all. Another disappearing partner perhaps (this time significant). What happened to the Development and Option Agreement with AZ? Shareholders deserve much better. Hello ASIC!!
I’ve been adamant for years that DEP-Docetaxel is a commercial dud and going nowhere. My position is now only strengthened by the fact that DEP-Docetaxel was not accepted for presentation at ASCO in June.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-8
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $41.20M | |||
| Open | High | Low | Value | Volume |
| 9.9¢ | 10.0¢ | 9.9¢ | $661 | 6.668K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 46932 | 9.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.0¢ | 5590 | 2 |
View Market Depth
| Last trade - 10.53am 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
9.9¢ |
Change
0.000 ( 1.00 %) |
||||
| Open | High | Low | Volume | ||
| 9.9¢ | 10.0¢ | 9.8¢ | 84063 | ||
| Last updated 11.14am 14/06/2024 ? | |||||
| SPL (ASX) Chart |